Poorly Differentiated and Undifferentiated Thyroid Carcinomas
Overview
Affiliations
Thyroid cancer is the most common endocrine malignancy and its incidence goes on increasing worldwide. The majority of thyroid tumours comprise well-differentiated (papillary and follicular) thyroid carcinomas that usually carry an excellent prognosis, while a minority progress to poorly differentiated carcinoma (PDTC) and, ultimately, to the highly aggressive and lethal undifferentiated carcinoma (UTC). Recently, some major advances have been made on the histologic and imunohistochemical identification, as well as on the molecular characterization of PDTC and UTC. In this review we summarize the most recent immunohistochemical and molecular findings in PDTC and UTC, giving a particular emphasis to the diagnostic and prognostic meaning of the genetic alterations.
Potential Therapeutic Agents against Paclitaxel-And Sorafenib-Resistant Papillary Thyroid Carcinoma.
Kim S, Park K, Lim J, Yun H, Kim S, Choi K Int J Mol Sci. 2022; 23(18).
PMID: 36142303 PMC: 9499486. DOI: 10.3390/ijms231810378.
Baldini E, Presutti D, Favoriti P, Santini S, Papoff G, Tuccilli C Int J Mol Sci. 2022; 23(7).
PMID: 35409084 PMC: 8999125. DOI: 10.3390/ijms23073724.
Choi J, Hong Y, Kim H, Jung A Thyroid Res. 2021; 14(1):24.
PMID: 34794464 PMC: 8603469. DOI: 10.1186/s13044-021-00115-z.
Mediastinal Thyroid Carcinoma and Graves' Disease: A Rare Presentation.
Lomelino Pinheiro S, Damasio I, Figueiredo A, Nunes da Silva T, Leite V Case Rep Endocrinol. 2021; 2021:6584616.
PMID: 34676120 PMC: 8526269. DOI: 10.1155/2021/6584616.
Boutzios G, Papaoiconomou E, Pikoulis A, Nastos K, Pouloudi D, Pikouli A Mol Clin Oncol. 2021; 15(4):200.
PMID: 34462656 PMC: 8375044. DOI: 10.3892/mco.2021.2362.